摘要
目的：通过服用吲哚美辛预防全髋关节置换术后异位骨化的发生以了解非甾体抗炎药抑制异位骨化形成的疗效。
方法：对2003-02/2005-02在郑州大学第一附属医院采用后外侧入路行人工全髋关节置换术后服用吲哚美辛的40例患者进行随访（用药组），对照组为1996-02/1999-02采用相同入路手术而在术后未服用吲哚美辛的40例患者。用药组术后第1天开始服用吲哚美辛，50 mg/次，2次/d，应用3周。术后3周、12周、3个月、6个月、12个月及实验结束前对患者进行随访，随访内容：摄X射线片（包括双髋正位、闭孔斜位、髂骨斜位片）观察有无异位骨化形成；同时根据改良的d’Aubigne和Postel评分标准对髋关节功能进行评估。
结果：用药组40例患者获完整随访资料，平均随访时间为21.2个月（6~37个月）。6例患者发生异位骨化，据Brooker分型：Ⅰ度4例，Ⅱ度2例，无严重异位骨化（Ⅲ、Ⅳ度）发生；异位骨化发生率为15%。对照组40例患者获完整随访资料，平均随访时间为27.1个月（5~60个月）随访。16例患者发生异位骨化，异位骨化发生率为40%，其中5例为严重异位骨化。两组患者异位骨化和严重异位骨化的发生率差异均有显著性意义（P < 0.05）。
结论：吲哚美辛对全髋关节置换术后异位骨化形成有一定的预防作用。
关键词：异位骨化；全髋关节置换术后；吲哚美辛

肖鹏，王庆雷，王建儒.全髋关节置换术后异位骨化与吲哚美辛的预防效应：同期非随机随访对照[J].中国组织工程研究与临床康复，2008，12(9):1659-1661 [www.zglckf.com/zglckf/ejournal/upfiles/08-9/9k-1659(ps).pdf]

Preventive effect of indomethacin on heterotopic ossification following total hip replacement: A non-randomized concurrent control study

Abstract
AIM: To investigate the effect of indomethacin on prevention of heterotopic ossification (HO) after operative treatment of total hip replacement.
METHODS: Forty patients taking indomethacin after total hip replacement were enrolled at First Hospital Affiliated to Zhengzhou University from February 2003 to February 2005 as medication group. Forty patients received the same operation were enrolled from February 1996 to February 1999 as control group. The patients in the medication group were taken indomethacin from the first day after operation, 50 mg/times, twice a day, for 3 weeks. The patients were successfully followed up immediately before the end of the operation, at weeks 3, 12, months 3, 6 and 12 after operation. Follow-up included X-ray at normal position of double hips, oblique position of obturator foramen and oblique position of iliac bone to assess the incidence of HO. Hip joint function was assessed according to modified d'Aubigne and Postel standards.
RESULTS: Follow-up was performed in 40 patients of the medication group. The follow-ups averaged 21.2 months (ranged from 6 to 37 months). HO occurred in six cases. According to Brooker evaluation of HO, four cases were rated as degree Ⅰ, two as degree Ⅱ, and none as degree Ⅲ or Ⅳ. The incidence of HO was 15%. In the control group, totally 40 patients were followed up, averagely 27.1 months ranged from 5-60 months. The incidence of HO was 40% (16/40). Five patients developed severe HO. Significant differences were found in the incidence of HO and severe HO of the two groups （P < 0.05）.
CONCLUSION: Oral administration of indomethacin can inhibit HO after total hip replacement.

Xiao P, Wang QL, Wang JR.Preventive effect of indomethacin on heterotopic ossification following total hip replacement: A non-randomized concurrent control study.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(9):1659-1661(China) [www.zglckf.com/zglckf/ejournal/upfiles/08-9/9k-1659(ps).pdf]